Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab. Meuth SG, Wolff S, Muck A, Willison A, et al. Ann Neurol 2024 Nov 25. doi: 10.1002/ana.27143.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Meuth SG, Wolff S, Muck A, Willison A, et al. Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab. Ann Neurol 2024 Nov 25. doi: 10.1002/ana.27143.
PMID: 39582359